FastTRK
Wed, 18 Mar 2020 to Fri, 31 Dec 2021

What is FastTRK?

FastTRK is a clinical testing program for the diagnosis of NTRK gene fusions. Sponsored by Bayer, this is a complimentary service for clinicians to determine whether their patients’ cancer has an NTRK gene fusion. Solid tumour samples from eligible patients (in the form of a solid tumour block or prepared slides) will be tested by immunohistochemistry (IHC) and/or next generation sequencing (NGS). Currently, Bayer has partnered with LifeLabs and the Kingston Health Sciences Centre
(KHSC) to provide NTRK gene fusion testing services for Canadians. The FastTRK program will be supported at least until the end of 2021. Please visit www.fasttrk.ca for more information.


What is the patient eligibility for this program?
All patients with solid tumours that are metastatic or when surgical resection is likely to result in severe morbidity, and for whom no satisfactory treatment options are available meet the criteria to be tested.


I have many patients to test. Which patients should be tested?
Considering the above eligibility criteria, testing for NTRK gene fusions should be performed for patients with the following tumour types:

  • Tumour types known to frequently harbour NTRK gene fusions (i.e. infantile fibrosarcoma, congenital mesoblastic nephroma, mammary analogue secretory carcinoma, and secretory breast cancer1).
  • Commonly diagnosed tumour types (e.g. lung cancer and colorectal cancer) known to be negative for other oncogenic alterations through exclusionary testing.
  • CRC patients with MSI-H/dMMR status2-4.
  • Thyroid cancer, salivary cancer, and sarcoma patients.


How do I access FastTRK and which requisition form do I use?

  1. Visit www.fasttrk.ca.
  2. To download the appropriate requisition form, you will need to indicate your hospital name. (The testing lab option will change based on your geographical location). Please use the appropriate requisition form (see table below).
  3. Please ensure that the patient eligibility and consent sections are completed.
  4. Coordinate with your local pathology department to ship a copy of the completed requisition form and required patient sample to the testing lab. Please refer to sample details section for more information.
  5. Shipping costs associated with mailing samples to and from originating hospital to centralized testing labs is covered under the FastTRK program. Please review to shipping details section as outlined on the requisition form.
  6. Turn-around time for the testing report will be anywhere from 2-15 business days depending on the outcome of the test(s).

 

What if my patient is diagnosed with an NTRK gene fusion?
If consent has been provided in the requisition form, Bayer Medical Affairs can be in contact with the clinician regarding additional medical information.


What if I have other questions?
Please review the requisition form for further information including details on shipping, sample preparation, patient eligibility criteria, technical specifications of the tests, etc. For any other inquiries, Health Care Practioners are welcome to email fasttrk@bayer.com to be in touch with a representative from Bayer Medical Affairs.